Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy

Cancer Immunology, Immunotherapy

Volumn 56, Issue 6, 2007, Pages 797-806

  Peng, Xiaohui ^a   Treml, John ^a   Paterson, Yvonne ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adjuvant; CD4+ T cell; CD8 + T cell; DNA vaccine; HPV 16 E7; Listeriolysin O

Indexed keywords

DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LISTERIOLYSIN O; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PROTEIN E7; TUMOR ANTIGEN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERA; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; LISTERIA MONOCYTOGENES; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR; TUMOR REGRESSION; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL TOXINS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEAT-SHOCK PROTEINS; HEMOLYSIN PROTEINS; LYMPHOCYTE ACTIVATION; MACROPHAGE INFLAMMATORY PROTEIN-1; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS E7 PROTEINS; PLASMIDS; RECOMBINANT PROTEINS; VACCINES, DNA;

EID: 34248186033     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0240-9     Document Type: Article

References (27)

1. Hoption Cann SA, van Netten JP, van Netten C (2003) Dr. William Coley and tumour regression: a place in history or in the future. Postgrad Med J 79:672
2. Pamer EG (2004) Immune responses to Listeria monocytogenes. Nat Rev Immunol 4:812
3. Pan ZK, Weiskirch LM, Paterson Y (1999) Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res 59:5264
4. Yoshimura K, Jain A, Allen HE, Laird LS, Chia CY, Ravi S, Brockstedt DG, Giedlin MA, Bahjat KS, Leong ML, Slansky JE, Cook DN, Dubensky TW, Pardoll DM, Schulick RD (2006) Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res 66:1096
5. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 87:796
6. Choo CK, Rorke EA, Eckert RL (1994) Differentiation-independent constitutive expression of the human papillomavirus type 16 E6 and E7 oncogenes in the CaSki cervical tumour cell line. J Gen Virol 75:1139
7. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21
8. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y (2001) Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 167:6471
9. Lamikanra A, Pan ZK, Isaacs SN, Wu TC, Paterson Y (2001) Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J Virol 75:9654
10. Peng X, Hussain SF, Paterson Y (2004) The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function. J Immunol 172:6030
11. Hussain SF, Paterson Y (2005) What is needed for effective anti-tumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV associated tumors. Cancer Immunol Immunother 54:577
12. Sewell DA, Shahabi V, Gunn GR, Pan ZK, Dominiecki ME, Paterson Y (2004) Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res 64:8821
13. Nagata T, Aoshi T, Uchijima M, Suzuki M, Koide Y (2004) Cytotoxic T-lymphocyte-, and helper T-lymphocyte-oriented DNA vaccination. DNA Cell Biol 23:93
14. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA (1997) DNA vaccines. Annu Rev Immunol 15:617
15. Ou-Yang P, Hwang LH, Tao MH, Chiang BL, Chen DS (2001) Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: role of dendritic cells. J Med Virol 66:320
16. Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, Jackson SS, Lifton MA, Freed DC, Perry HC, Davies ME, Shiver JW, Letvin NL (2002) Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 168:562
17. Haddad D, Ramprakash J, Sedegah M, Charoenvit Y, Baumgartner R, Kumar S, Hoffman SL, Weiss WR (2000) Plasmid vaccine expressing granulocyte-macrophage colony stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol 165:3772
18. McKay PF, Barouch DH, Santra S, Sumida SM, Jackson SS, Gorgone DA, Lifton MA, Letvin NL (2004) Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur J Immunol 34:1011
19. Choo AY, Choo DK, Kim JJ, Weiner DB (2005) DNA vaccination in immunotherapy of cancer. Cancer Treat Res 123:137
20. Kim TW, Lee JH, He L, Boyd DA, Hung CF, Wu TC (2005) DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen. Hum Gene Ther 16:26
21. Kim TW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, Pai SI, Chen PJ, Lin CT, Boyd DA, Wu TC (2004) Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 11:1011
22. Kim TW, Hung CF, Boyd DA, He L, Lin CT, Kaiserman D, Bird PI, Wu TC (2004) Enhancement of DNA vaccine potency by co-administration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res 64:400
23. Kim TW, Hung CF, Boyd D, Juang J, He L, Kim JW, Hardwick JM, Wu TC (2003) Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 171:2970
24. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC (2001) Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108:669
25. Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, Wu TC (2000) Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60:1035
26. Decatur AL, Portnoy DA (2000) A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science 290:992
27. Lety MA, Frehel C, Dubail I, Beretti JL, Kayal S, Berche P, Charbit A (2001) Identification of a PEST-like motif in listeriolysin O required for phagosomal escape and for virulence in Listeria monocytogenes. Mol Microbiol 39:1124